Trial · NCT04273802
CPX-351 in Higher Risk Myelodysplastic Syndromes
NCT04273802, Phase 1, Phase 2, Completed, Groupe Francophone des Myelodysplasies
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CPX-351 in Higher Risk Myelodysplastic Syndromes. Trials, record NCT04273802. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04273802
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CPX-351 in Higher Risk Myelodysplastic Syndromes
- NCT number
- NCT04273802
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- Groupe Francophone des Myelodysplasies
- Conditions
- Myelodysplastic Syndromes
- Interventions
- CPX-351 in cohort A, CPX-351 in cohort B
- First posted
- 2020-02-18
- Last updated
- 2022-07-07
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response rate (CR, CRi, PR) | 28 to 42 days after induction | Response to induction therapy |
| Secondary | Overall response rate (CR, CRi, PR, HI) | 28 to 42 days after induction | Response to induction therapy |
| Secondary | Event free survival | 42 months | Event free survival |
| Secondary | Response duration | 42 months | Duration of the response to induction therapy |
| Secondary | Overall survival | 42 months | Overall survival |
| Secondary | Toxicity profile - Duration of cytopenias | 42 months | Duration of cytopenias |
| Secondary | Toxicity profile - life threatening or fatal cytopenias | 42 months | Number of life threatening or fatal cytopenias |
| Secondary | Toxicity profile - hospitalization | 42 months | Time spent in hospital for induction and consolidation cycles |
| Secondary | Evaluation of minimal residual disease (MRD) after induction and after the last consolidation | 42 months | Evaluation of MRD by flow cytometry |
| Secondary | Evaluation of minimal residual disease (MRD) after induction and after the last consolidation | 42 months | Evaluation of variant allelic frequency (VAF) of Baseline mutations |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37245522 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04273802
GET https://conductscience.org/api/trials/v1/NCT04273802/registered